Brass Tax Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Brass Tax Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-353	Closed	-$224K	–	239
2025 Q1	$224K	Hold	353	–	–	0.05%	197
2024 Q4	$251K	Hold	353	–	–	0.05%	174
2024 Q3	$371K	Hold	353	–	–	0.08%	118
2024 Q2	$371K	Hold	353	–	–	0.16%	77
2024 Q1	$340K	Buy	+353	New	+$336K	0.18%	72

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Brass Tax Wealth Management's REGN Position: Q2 2025 in Review

Brass Tax Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 353 shares — an estimated $224K sold.

Brass Tax Wealth Management first reported a position in REGN in Q1 2024 and held it in 5 quarters. The position peaked at $371K in Q3 2024. 1,203 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Brass Tax Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Brass Tax Wealth Management sold 353 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $224K.
Brass Tax Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 5 quarters.
Brass Tax Wealth Management's Regeneron Pharmaceuticals position peaked at $371K in Q3 2024.
1,203 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Brass Tax Wealth Management's 13F filing for Q2 2025, filed 11 Aug 2025.